CG Oncology Stock Soars After Bladder Cancer Drug Cuts Recurrence Risk by 68% in Pivotal Phase 3 Trial Win
Shares of CG Oncology Inc. jumped on Monday after the biotechnology company said its experimental bladder cancer therapy sharply reduced the risk of the disease coming back in a late-stage trial.
The stock rose $8.53, or 11.47%, to $82.93 in early trading on the Nasdaq. Earlier, the shares had jumped more than 30% in premarket trading before giving back part of those gains after the opening bell.
About 1.84 million shares had changed hands early in the session, well above the stock's three-month average daily volume of about 999,000. The company's market value stands at about $7.4 billion.
Trial meets main goal
CG Oncology said its Phase 3 PIVOT-006 trial met its primary goal. The 367-patient study tested cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with intermediate-risk non-muscle invasive bladder cancer after their tumors had been completely removed.
The therapy reduced the risk of cancer recurrence........
